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Enhanced glucose utilization can be visualized in
atherosclerotic lesions and may reflect a high glyco-
lytic rate in lesional macrophages, but its causative
role in plaque progression remains unclear. We
observe that the activity of the carbohydrate-respon-
sive elementbindingproteinChREBP is rapidly down-
regulated upon TLR4 activation in macrophages.
ChREBP inactivation refocuses cellular metabolism
to a high redox state favoring enhanced inflammatory
responses after TLR4 activation and increased cell
death after TLR4 activation or oxidized LDL loading.
Targeted deletion of ChREBP in bone marrow cells
resulted in accelerated atherosclerosis progression
in Ldlr/ mice with increased monocytosis, lesional
macrophage accumulation, and plaque necrosis.
Thus, ChREBP-dependent macrophage metabolic
reprogramming hinders plaque progression and es-
tablishes a causative role for leukocyte glucosemeta-
bolism in atherosclerosis.INTRODUCTION
Atherosclerosis is a chronic inflammatory disease driven by
the accumulation of macrophage foam cells in the artery walls
(Ross, 1999; Hansson et al., 2006; Moore and Tabas, 2011).
Circulatingmonocytes traverse the inflamed arterial endothelium
to fuel developing lesions (Swirski and Nahrendorf, 2013; Zer-
necke and Weber, 2014; Randolph, 2014; Tall and Yvan-Char-
vet, 2015). In addition, local environmental cues lead to alter-
ations in the phenotype and survival of lesional macrophages
(Tabas, 2005; Mosser and Edwards, 2008; Van Vre´ et al., 2012;
Chinetti-Gbaguidi and Staels, 2011; Hasty and Yvan-Charvet,
2013), altering plaque composition and increasing the vulnera-
bility of the plaques to rupture (Libby et al., 1996; Kolodgie
et al., 2004).132 Cell Reports 13, 132–144, October 6, 2015 ª2015 The AuthorsAlthough extensive research has focused on elucidating the
roles of cytokines and the microenvironment in the migration,
proliferation, differentiation, and apoptosis of monocytes and
macrophages, the cellular metabolic pathways that regulate
these processes are not well understood. Inflamed atheroscle-
rotic plaques can be visualized by non-invasive positron emis-
sion tomography-computed tomography (PET-CT) imaging
with 18FDG, a glucose analog, which correlateswithmacrophage
accumulation and inflammation (Rogers and Tawakol, 2011;
Garcia-Garcia et al., 2014). Increasing glucose metabolism is
thought to be crucial for macrophage activation. For instance,
glucose consumption and glycolysis are enhanced in macro-
phages during inflammatory responses (Fukuzumi et al., 1996;
Gamelli et al., 1996), and pharmacological inhibition of glucose
metabolism can prevent the inflammatory responses induced
by lipopolysaccharide (LPS) (Gautier et al., 2013). However, a
recent study has called into question the relevance of these ob-
servations, as myeloid-specific overexpression of the glucose
transporter Glut1, achieved by transducing bone marrow (BM)
with CD68-Glut1 retroviral particles, did not aggravate athero-
sclerosis in Ldlr/ knockout mice compared to Glut1-sufficient
controls despite enhanced macrophage glycolysis (Nishizawa
et al., 2014). Thus, there is a need for a better understanding of
the metabolic pathways that link macrophage cellular glucose
homeostasis and inflammation in atherosclerosis.
There are a number of pathways leading to aberrant meta-
bolism of glucose that are thought to be pathological. Studies
in mice have shown that glucose can be reduced by aldose
reductase (AR) to sorbitol in macrophages, leading to the pro-
duction of excess reactive oxygen species (ROS), which may
contribute to accelerated atherosclerosis (Srivastava et al.,
2009; Vedantham et al., 2011; Vikramadithyan et al., 2005). How-
ever, low levels of AR are present in mice, and this pathway
has few effects in mouse macrophages unless they express a
human AR transgene, suggesting that alternative metabolic
pathways exist to drive the inflammatory responses observed
during macrophage activation. Modulation of mitochondrial po-
tential and the tricarboxylic (TCA) cycle has been clearly associ-
ated with the ability of macrophages to mount an inflammatory
response (Vats et al., 2006; O’Neill and Hardie, 2013; Tannahill
et al., 2013; Jha et al., 2015). Recently, the sedoheptulose kinase
CARKL, an enzyme involved in the pentose phosphate pathway
(PPP), has been proposed to act upstream of these alterations
by modulating glycolysis, oxidative phosphorylation (OXPHOS),
and the TCA cycle in macrophages, with subsequent modula-
tion of inflammatory responses (Haschemi et al., 2012). Intri-
guingly, the carbohydrate-responsive element-binding protein
(ChREBP), also known asMLX-interacting protein-like (MLXIPL),
is a glucose-responsive transcription factor that regulates gly-
colysis and lipogenesis in hepatocytes. ChREBP can also be
either positively regulated by glucose-derived metabolites or
negatively regulated by AMPK and PKA, illustrating its pivotal
role at the interface of different metabolic pathways (Filhoulaud
et al., 2013). However, the relevance of this pathway to macro-
phage activation and atherosclerosis remains unknown.
To test the causal relationship between modulation of myeloid
glucose utilization, inflammatory activation of myeloid cells,
and the development of atherosclerotic lesions, we examined
the role of ChREBP in inflammatory macrophages. We found
that ChREBP activity was downregulated upon LPS stimula-
tion, and knockdown of ChREBP in macrophages led to a
major defect in the metabolic pathways that generate NADPH,
the rate-limiting source of reduced glutathione. This led to
increased inflammatory cytokine production and increased
apoptosis in response to both LPS and oxidized LDL after
ChREBP knockdown in macrophages. We next transplanted
the BM ofmicewith ChREBP deficiency into atheroprone Ldlr/
mice. Unexpectedly, we found that Ldlr/ mice that had
received Chrebp/ BM showed accelerated atherosclerosis,
with macrophage accumulation and enhanced necrotic core for-
mation. These data demonstrate an important anti-inflammatory
and pro-survival role for ChREBP in the prevention of atheroscle-
rosis and necrotic core formation.
RESULTS
ChREBP Deficiency Increases Expression of
Inflammatory Cytokines in Macrophages
Given the enhanced glucose flux observed in inflammatory mac-
rophages (Fukuzumi et al., 1996; Gamelli et al., 1996; Gautier
et al., 2013; Nishizawa et al., 2014), we first investigated whether
the activity of ChREBP, a glucose-responsive transcriptional
factor, was enhanced upon LPS stimulation in thioglycollate-
elicited peritoneal macrophages. Surprisingly, ChREBP nuclear
translocation, reflecting ChREBP activity, was reduced by 2-
fold after 3 hr of LPS stimulation in wild-type (WT) macrophages
(Figures 1A and 1B). In an attempt to identify the underlying
mechanism, we next tested whether reduced CARKL-depen-
dent X5P production upon macrophage activation (Haschemi
et al., 2012) could prevent ChREBP nuclear translocation and
activity (Filhoulaud et al., 2013). Intriguingly, CARKL silencing us-
ing small interfering RNA (siRNA) reduced ChREBP nuclear
translocation both at baseline and after LPS stimulation, but
this most likely reflected reduced total ChREBP protein expres-
sion (Figure S1). Mechanistic studies were next carried out using
siRNA that led to a significant decrease in ChREBP mRNA
expression (Figure S2A). ChREBP protein expression and nu-Cclear translocation confirmed the knockdown efficiency (Figures
1A and 1B). A time-course experiment showed a greater initial in-
crease in the expression of genes encoding cytokines such as
tumor necrosis factor a (TNF-a) and interleukin-6 (IL-6) in macro-
phages after ChREBP silencing, which returned to basal levels
after 10 hr of LPS exposure (Figures 1C and 1D). A 2-fold in-
crease in TNF-a and IL-1b secretion paralleled the mRNA
response 3 hr after LPS challenge (Figure 1E). These data,
together with enhanced surface staining of the co-stimulatory
molecule CD80 upon LPS stimulation in ChREBP knockdown
macrophages (Figure 1F), demonstrated an enhanced activation
state of these cells. LPS is known to signal via the Toll-like recep-
tor 4 (TLR4)/nuclear factor kB (NF-kB) pathway, and ChREBP
knockdown resulted in a greater initial increase and sustained
phosphorylation in the transactivation domain of the p65 subunit,
which is essential for optimal NF-kB activation after LPS expo-
sure (Figure 1G). An alkaline phosphatase reporter construct
inducible by NF-kB in RAW-Blue cells confirmed an increase in
NF-kB transcriptional activity after ChREBP silencing from 3 hr
to 6 hr after LPS stimulation (Figure 1H). This appears to be spe-
cific to the NF-kB pathway, as similar phosphorylation of Akt,
p38-MAPK, and mTor was observed after ChREBP knockdown
in macrophages 3 hr after LPS treatment (Figure S2B). We finally
evaluated cytokine gene expression BM-derived macrophages.
Although there was no detectable basal expression of cytokines
in either controls or ChREBP knockdown macrophages, an
enhanced response to LPS was confirmed in ChREBP knock-
down BM-derived macrophages (Figure S2C). Thus, ChREBP
downregulation after LPS stimulation affects the inflammatory
response in macrophages.
Metabolic Profiling Reveals Reduced Metabolic
Pathways that Control NADPH Production in
LPS-Stimulated Chrebp-Deficient Macrophages,
Favoring Catabolic over Anabolic Pathways
Considering the substantial reprogramming of metabolism upon
macrophage activation, we next quantified glycolytic metabo-
lites by liquid chromatography-mass spectrometry in thioglycol-
late-elicited peritoneal macrophages after ChREBP knockdown
with or without 3 hr LPS treatment. Unexpectedly, despite the
role of ChREBP as a positive regulator of glycolysis in hepato-
cytes (Dentin et al., 2012), increases in glycolytic metabolites
such as fructose 1,6-biphosphate (FBP) and 3-phosphoglyc-
erate/2-phosphoglycerate (3PG+2PG) were observed in basal
ChREBP knockdown macrophages even thought these effects
were not sustained upon LPS stimulation (Figure 2A). Glucose
6-phosphate/fructose 6-phosphate (G6P+F6P) and citric acid
cycle metabolites such as citrate/isocitrate (I/Citrate) and succi-
nate were not statically different in macrophages following
ChREBP silencing (Figures 2A and 2B). In contrast, a striking
increase in malate (more than 3-fold) was observed in basal
and LPS-stimulated ChREBP knockdown macrophages (Fig-
ure 2B). This was associated with a trend toward a higher
ATP-to-ADP ratio in basal ChREBP knockdown macrophages
(Figure 2C, left panel) and an 1.6-fold increase in lactate con-
tent (a surrogate of glycolytic flux) in basal and LPS-stimulated
ChREBP knockdown macrophages (Figure 2C, right panel).
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Figure 1. ChREBP Is Required for the Proper Inflammatory Response of Macrophages
Thioglycollate-elicited peritoneal macrophages transfected for 48 hr with scrambled or ChREBP siRNA were stimulated with or without 100 ng/ml LPS for 3 hr or
the indicated period of time.
(A and B) Representative pictures and quantification of ChREBP translocation (magnification 53, insert 203 with or without DAPI co-staining).
(C and D) mRNA expression over time of TNF-a and IL-6.
(E) Secretion of inflammatory cytokines normalized to cellular protein amount and expressed as a percentage of WT.
(F and G) CD80 surface expression (F) and phospho-p65 expression (G) over time.
(H) NF-kB activity measured by an alkaline phosphatase reporter construct in RAW-Blue cells.
Values are mean ± SEM of three independent experiments. *p < 0.05 compared to control; xp < 0.05 versus untreated condition.
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Figure 2. ChREBP Reprograms Carbohy-
drate Metabolism in LPS-Stimulated Macro-
phages
Thioglycollate-elicited peritoneal macrophages
transfected with scrambled or ChREBP siRNA
were stimulated with or without 100 ng/ml LPS for
3 hr or the indicated period of time.
(A–C) Effect of LPS treatment on glycolytic (A) and
citric acid (B) metabolites and ATP/ADP ratio and
lactate (C).
(D and E) ECAR (D) and OCR (E) recordings of 3-hr
LPS-stimulated macrophages under the indicated
conditions.
(F–J) Effect of LPS treatment on mRNA expression
of glycolytic enzymes (F), metabolites from the
pentose phosphate pathway (G), PGD activity and
NADPH/NAD ratio (H), ME activity and glucose
conversion into lipids (I), and mRNA expression of
NADPH-dependent enzymes (J).
(K) ChIP assays were performed with amplicons
flanking the proximal promoter region of putative
ChREBP targets. qPCR (normalized to input) was
used to assess ChREBP occupancy of the targeted
promoter.
(L) Effect of LPS on cytokine gene expression in
macrophages transfected with scrambled, ME2,
and PDG siRNA.
Results are means ± SEM of an experiment per-
formed in triplicate. *p < 0.05 compared to control;
x p < 0.05 versus untreated condition.
(M) Schematic representation of the metabolic
pathways regulated by ChREBP in LPS-treated
macrophages.
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Figure 3. The Enhanced Inflammatory Res-
ponse in Chrebp-Deficient Macrophages Is
Metabolically Driven by Low Glutathione
Redox Status
Thioglycollate-elicited peritoneal macrophages
transfected with scrambled or ChREBP siRNA
were stimulated with or without 100 ng/ml LPS for
3 hr or the indicated period of time.
(A–D) Representative histograms and quantifica-
tion of ROS generation (A and B) and intracellular
thiol content (C and D).
(E) Intracellular GSH/GSSG ratio.
(F) Effect of GSH on transcript levels of inflamma-
tory cytokines (percentage over WT).
Results are means ± SEM of three independent
experiments. *p < 0.05 compared to control; xp <
0.05 versus untreated condition.upon activation was also confirmed by an increase in extra-
cellular acidification rate (ECAR) at baseline and after glucose
stimulation, but not after oligomycin treatment (Figure 2D),
and a decrease in oxygen consumption rate (OCR) at baseline
or after oligomycin treatment (Figure 2E). An 2-fold increase
in the expression of glycolytic enzymes such as hexokinase
2 (Hk2) and pyruvate kinase isozyme M2 (PKM2) in LPS-stimu-
lated macrophages after ChREBP knockdown also correlated
with higher glycolytic flux (Figure 2F). Although increased
6-phosphogluconate (6PG) was observed in basal and LPS-
stimulated macrophages after ChREBP silencing, there was a
significant decrease in ribulose-5-phosphate/xybulose-5-phos-
phate (R5P/X5P) levels, but not sedoheptulose-7phosphate/se-
doheptulose (S7P/SED), in these cells (Figure 2G). This was
associated with an 2-fold decrease in phosphogluconate de-
hydrogenase (PGD; an enzyme that converts 6PG into R5P
and NADP+ to NADPH) activity in basal and LPS-stimulated
ChREBP knockdown cells (Figure 2H, left panel). Consistently,
basal and LPS-stimulated macrophages exhibited a prominent
30-fold decrease in the NADPH/NADP ratio after ChREBP
knockdown (Figure 2H, right panel). NADPH can also be pro-
duced by the pyruvate cycling pathway or consumed through
anabolic pathways such as lipid synthesis, both pathways being
targets of ChREBP (Ma et al., 2006; Burgess et al., 2008; Filhou-
laud et al., 2013). Remarkably, we found a 2.5-fold decrease in
malic enzyme (ME) activity (Figure 2I, right panel) and a 2-fold
decrease in glucose conversion into lipids (Figure 2I, left panel)
in basal and LPS-stimulatedmacrophages after ChREBP knock-136 Cell Reports 13, 132–144, October 6, 2015 ª2015 The Authorsdown. At the transcriptional level, an
2-fold decrease in phosphogluconate
dehydrogenase (PGD), mitochondrial ma-
lic enzyme (ME2), and fatty acid synthase
(FAS) mRNA expression was observed in
basal and LPS-stimulated macrophages
after ChREBP silencing (Figure 2J), and
this correlated with an altered NADPH/
NAPD ratio and impaired lipid synthesis.
Then, specific binding of ChREBP on
FAS, ME2, and PGD promoters was
investigated in basal and LPS-stimulatedmacrophages using chromatin immunoprecipitation assays.
The binding of ChREBP was demonstrated at different degrees
on these promoters and declined after 3-hr LPS stimulation (Fig-
ure 2K). ME2 and PGD silencing using siRNA in thioglycollate-eli-
cited peritoneal macrophageswith or without 3-hr LPS treatment
also confirmed that combined knockdown of these two genes
led to an exacerbated inflammatory response after LPS stimula-
tion (Figure 2L). Together, our results reveal that ChREBP does
not contribute to the enhanced glycolysis in inflamed macro-
phages but rather controls the two main cellular pathways
involved in NAPDH production, which could explain, together
with reduced FAS expression, the diminished lipid synthesis ca-
pacity of these cells (Figure 2M).
Reduced PPP-Dependent Cellular Redox Status Drives
the Macrophage Inflammatory Response in Chrebp-
Deficient Macrophages
In metabolic terms, the reduced NADPH/NADP ratio observed
in macrophages after ChREBP silencing could equate to a lack
of reducing energy known to supply reduced glutathione and
scavenge free radicals to prevent oxidative damage. Indeed, a
time-course experiment revealed that ChREBP knockdown in
thioglycollate-elicited peritoneal macrophages led to an 1.7-
fold increase in the oxidative stress response measured by
flow cytometry (Figures 3A and 3B) that was inversely correlated
with an 1.4-fold decrease in thiol-tracker staining under basal
or LPS-stimulated conditions (Figures 3C and 3D). Increased
oxidative stress response was also observed to a less extent in
thioglycollate-elicited peritoneal macrophages cultured in low-
glucose medium (5.6 mM versus 25mM) after ChREBP silencing
(Figure S3). The reduced GSH/GSSG balance in basal (1.3-fold)
and LPS-stimulated (1.4-fold) macrophages after ChREBP
knockdown confirmed an alteration of the glutathione redox bal-
ance in these cells (Figure 3E). Remarkably, exogenous addition
of glutathione monoethyl ester clearly abolished the increased
inflammatory cytokine expression induced by LPS in thioglycol-
late-elicited peritoneal macrophages after ChREBP silencing
(Figure 3F). Together, these findings show that the increased in-
flammatory responses in macrophages with ChREBP silencing
reflect a lack of NADPH-dependent reduction of glutathione
disulfide.
Reduced M2 Polarization in Chrebp-Deficient
Macrophages
As the modulation of the redox status alters macrophage M2
polarization (Vats et al., 2006; Haschemi et al., 2012; Jais
et al., 2014), we next investigated the relevance of ChREBP in
this pathway. Nuclear translocation of ChREBP was increased
by almost 2-fold after IL-4 stimulation in thioglycollate-elicited
peritoneal macrophages (Figures S4A and S4B). A time-course
experiment showed that ChREBP silencing partially prevented
the initial increase in Arg1 and Mrc1 mRNA expression induced
by IL-4 (Figures S4C and S4D). Interestingly, treatment of IL-4-
stimulated ChREBP knockdown macrophages with the anti-
oxidant glutathione restored Arg1, Mrc1, and Fizz1 mRNA
expression to the level of control cells, suggesting that ChREBP
acts at the interface between macrophage M1-M2 polarization
by controlling the redox status of the cells and most likely
‘‘pre-programming’’ macrophage skewing (Figure S4E) (Jais
et al., 2014). As autophagy controls the delivery of lipids to lyso-
somes for hydrolysis (Ouimet et al., 2011) and lysosomal lipol-
ysis has recently emerged as critical for M2 activation (Huang
et al., 2014), we next wondered whether the altered fatty acid
homeostasis in macrophages after ChREBP knockdown could
modulate this pathway. ChREBP silencing prevented the rise
in autophagic flux induced by IL-4 as quantified by flow cytom-
etry (Figure S4F). Moreover, inhibition of autophagy by 3-meth-
yladenine (3-MA) reduced the polarization of M2 macrophages
induced by IL-4 in control macrophages to the same extent as
that in ChREBP knockdown macrophages, as measured by
Arg1, Mrc1, and Fizz1 mRNA expression (Figure S4E). Together,
these findings suggest that ChREBP controls autophagy-
dependent M2 polarization by maintaining macrophage redox
status and fatty acid production.
Increased Susceptibility of Chrebp-Deficient
Macrophages toCell Death Induced by LPS andOxidized
LDL-Dependent ROS Generation
To test whether the reduced redox state of macrophages after
ChREBP silencing contributes to an increased susceptibility
to oxidative stress-induced apoptosis, thioglycollate-elicited
peritoneal macrophages were treated with 100 ng/ml LPS or
50 mg/ml oxidized LDL for 24 hr. As expected, flow cytometry
analysis revealed that WT macrophages were alive 24 hr after
treatment (Figures 4A and 4B), whereas ChREBP knockdown
macrophages showed a dramatic 4-fold increase in macro-Cphage death, reflected by late apoptosis or necrosis (i.e.,
AnnexinV+ PI+) (Figures 4A and 4B). While reduced cellular
thiols were present in viable, apoptotic, and necrotic macro-
phages after ChREBP knockdown in all the treatment groups
(Figure 4C), the increase in ROS formation was mainly attribut-
able to cells undergoing apoptosis and necrosis (Figure 4D).
Because LPS and oxidized LDL-induced ROS production can
promote caspase-dependent cell death in macrophage foam
cells (Yvan-Charvet et al., 2010a), and recent data have shown
an intimate link between glucose metabolism and caspase
activation in experimental model of apoptosis induced by staur-
osporine (Pradelli et al., 2014), we next measured caspase
activity. Flow cytometry analysis of fluorescent label carboxy-
fluorescein (FAM) fluorescent-labeled inhibitor of caspases
(FICA) revealed an increase in caspase activity in apoptotic
and necrotic ChREBP knockdown macrophages upon LPS or
oxidized LDL stimulation compared to controls (Figures 4E
and 4F). The addition of glutathione or pharmacological inhibi-
tion of caspases by Z-VAD-FMK confirmed marked antiapop-
totic effects in oxidized LDL-stimulated Chrebp-deficient mac-
rophages (Figure 4G). Together, these findings reveal a role of
ChrREBP in maintaining macrophage redox status to limit cas-
pase-dependent death.
Accelerated Atherosclerosis in Ldlr/ Mice
Transplanted with Chrebp/ BM
Atherosclerosis is a chronic inflammatory disease dominated
by a phenotypic switch of macrophages (Hasty and Yvan-Char-
vet, 2013) and alteration of macrophage survival (Tabas, 2005;
Van Vre´ et al., 2012). We wondered whether expression of
ChREBP by macrophages might affect atherosclerosis devel-
opment. To test this hypothesis, we transplanted BM cells
from WT and Chrebp/ mice into irradiated Ldlr/ recipients,
thereby generating Ldlr/ mice with either Chrebp/ or WT
macrophages. Four weeks after transplantation, mice were
challenged with a Western-type diet for 11 weeks. Freshly iso-
lated resident peritoneal macrophages at the end of the ex-
periment showed no detectable ChREBP mRNA expression.
TNF-a expression was increased by 2.5-fold and that of
MCP-1 by 1.6-fold (Figure 5A), similar to the enhanced TNF-a
and MCP-1 mRNA expression observed in LPS-stimulated
Chrebp/ thioglycollate-elicited peritoneal macrophages iso-
lated from chow-fed animals compared to controls (Figure S5).
This confirmed the efficiency of the transplantation procedure.
Lipoprotein and metabolic parameters were measured before
the start of the diet and at the time of sacrifice. As shown in
Table S2, the two groups of mice did not differ significantly
with regards to body weight, fat mass, plasma leptin, glucose
and triglyceride levels, or plasma LDL and HDL cholesterol.
We also did not observe changes in blood leukocytes, lympho-
cytes or spleen weight in Chrebp/ BM transplanted mice
before the start or at the end of the experiment (Table S2). A
role of ChREBP in mediating glycolysis-induced T cell activa-
tion (Macintyre et al., 2014) was also excluded in Chrebp/
BM recipients, as a similar percentage of CD44hiCD62Llo pe-
ripheral CD4+ and CD8+ lymphocytes was observed at sacrifice
(Figure S6). Nevertheless, Ldlr/ mice receiving Chrebp/ BM
showed an 1.7-fold increase in atherosclerosis developmentell Reports 13, 132–144, October 6, 2015 ª2015 The Authors 137
Figure 4. Enhanced Susceptibility to Cell Death in Chrebp-Deficient Macrophages Macrophages
(A and B) Representative FACS plots (A) and quantification ofmacrophage death (B) in thioglycollate-elicited peritoneal macrophages transfectedwith scrambled
or ChREBP siRNA and treated with 100 ng/ml LPS or 50 mg/ml oxidized LDL (oxLDL) for 16 hr.
(C and D) Thiols (C) and ROS repartition (D) in necrotic, apoptotic, and viable cells.
(E and F) Representative histograms (E) and quantification (F) of caspase activation.
(G) Effect of GSH and Z-VAD-FMK caspase inhibitor on the percentage of Annexin V+ cells after 16-hr treatment with 50 mg/ml oxLDL.
Values are mean ± SEM. *p < 0.05 compared to control.
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Figure 5. ChREBPDeficiency Promotes Accelerated Atherosclerosis
(A) mRNA levels in resident peritoneal macrophages isolated from high-fat
diet (HFD)-fed Ldlr/ recipient mice transplanted with WT or Chrebp/ BM.
(B) Representative H&E staining (magnification 1003, insert 2003) and
quantification of atherosclerotic lesion development in the proximal aorta of
HFD-fed Ldlr/mice transplanted with WT or Chrebp/ BM (n = 10). Arrows
and dashed lines depict inflammatory infiltrates.in their proximal aortas and showed numerous inflammatory
infiltrates compared to mice receiving WT BM, which devel-
oped only sparse foam cell-containing atherosclerotic lesions
(Figure 5B).
Monocytosis in Chrebp/ BM-Transplanted Ldlr/
Mice Is Mediated through a Cell-Extrinsic Mechanism
Immunohistochemical staining of aortic root plaques confirmed
a 2-fold increase in F4/80+ macrophages in Chrebp/ BM-
transplanted Ldlr/ mice (Figure 6A). The increased plaque
macrophage content in Chrebp/ atheromata could reflect
local inflammation or systemic monocytosis, which are known
to contribute to atherosclerotic plaque progression in bothCmice and humans (Coller, 2005; Swirski et al., 2007; Tacke
et al., 2007; Combadie`re et al., 2008). We observed a 2-fold
increase in neutrophils and inflammatory blood Ly6Chi mono-
cyte subsets in Chrebp/ BM-transplanted Ldlr/ mice fed
a high-fat diet (Figure 6B). We next undertook studies to eluci-
date the mechanisms underlying the peripheral inflammatory
phenotype observed in these mice. Targeted gene expression
profiling revealed that ChREBP was barely detectable in BM
progenitors compared to macrophages (Figure S7A), even
though ChREBP expression in these cells was much lower
than in hepatocytes (Figure S7B). Gavage with a liver X recep-
tor (LXR) agonist (TO-901317) that has been previously sug-
gested to increase ChREBP expression in hepatocytes (Cha
and Repa, 2007; Denechaud et al., 2008) did not modulate
macrophage ChREBP expression (Figure S7A). ChREBP was
also barely expressed in splenic dendritic cells or B and T
lymphocytes compared to macrophages (Figure S7C). Taking
advantage of a publically available gene expression dataset
from Immgen (http://www.immgen.org), we observed that key
enzymes of the PPP were predominantly expressed in cells
derived from the macrophage lineage (Figure S7D), paralleling
ChREBP expression. This further illustrated an important un-
recognized role of this pathway in macrophages. Consistent
with these findings, neither the LinSca1+cKit+ (LSK) popula-
tion, representing hematopoietic stem and progenitor cells
(HSPCs), nor the granulocyte-monocyte progenitor (GMP)
and common myeloid progenitor (CMP) populations were
altered in the BM of mice transplanted with Chrebp/ BM (Fig-
ure 6C). Nevertheless, monocyte counts were reduced in the
BM of mice that had received Chrebp/ BM, and this con-
trasted with the increase in Ly6Chi monocytes observed in their
spleen, most likely reflecting monocyte mobilization (Figures
2C and 2D). Measurement of various plasma factors known
to promote BM hematopoietic cell mobilization did not reveal
an alteration in growth factors such as GH, M-CSF or G-CSF
(Figure S7E) or chemoattractant molecules such as MIP1a,
MIP2, or KC (Figure S7F) in mice transplanted with Chrebp/
BM. However, there was a significant 1.5-fold increase in levels
of plasma MCP-1 and MCP-3, but not MCP-5, in these mice
(Figure 6E). These chemokines have been previously been
shown to be produced by macrophage foam cells (Westerterp
et al., 2013) and to promote CCR2-dependent monocyte mobi-
lization from the BM to the blood (Tsou et al., 2007). Thus, we
wondered whether the monocytosis observed upon myeloid
ChREBP deficiency could be dependent on systemic inflam-
mation driven by macrophages. To directly test our hypothesis,
we performed a competitive BM transplantation. Ldlr/ mice
were transplanted with a 1:1 mix of CD45.1 WT with either
CD45.2 WT or CD45.2 Chrebp/ BM. Mice were fed a high
fat diet, and monocyte levels were assessed. In line with our
previous observations, more CD45.2 Ly6Chi monocytes were
observed in mice containing Chrebp/ cells (Figure 6F). Inter-
estingly, the presence of CD45.2 Chrebp/ BM, but not of
CD45.2 WT BM, increased the number of CD45.1 WT periph-
eral monocytes, suggesting that monocyte mobilization in
mice that had received Chrebp/ BM was mediated by circu-
lating factors (Figure 6F). Thus, the monocytosis in mice that
had received Chrebp/ BM was most likely secondary to theell Reports 13, 132–144, October 6, 2015 ª2015 The Authors 139
Figure 6. Increased Lesional Macrophages and Inflammatory Monocytes in Mice Transplanted with Chrebp/ BM
(A) Representative pictures and quantification of F4/80+ macrophages in the proximal aorta (magnification 3100) of Ldlr/ mice transplanted with WT or
Chrebp/ BM (n = 10).
(B) Representative FACS plots and quantification of peripheral blood myeloid cells.
(C–E) Quantification of BM HSPCs and monocytes (C), splenic monocytes (D), and plasma MCP-1, 3, and 5 levels (E) in these mice.
(F) Competitive BM transplantation of WT CD45.1+ BM equally mixed with either CD45.2+ WT BM or CD45.2+ Chrebp/ BM and transplanted into Ldlr/
recipient mice fed for 11 weeks on an HFD (n = 8). Circulating Ly6hi monocytes were analyzed.
Values are mean ± SEM. *p < 0.05 compared to control.increased plaque burden and associated systemic inflamma-
tion. Future studies using specific knockout of ChREBP in mac-
rophages may help to decipher whether these cells are respon-
sible for the MCP-1 and MCP-3-dependent monocytosis.140 Cell Reports 13, 132–144, October 6, 2015 ª2015 The AuthorsIncreased Plaque Complexity in Ldlr/ Mice
Transplanted with Chrebp/ BM
Histological characterization of atherosclerotic lesions revealed
increased plaque complexity inmice that had receivedChrebp/
Figure 7. Increased Atherosclerotic Plaque Complexity in Mice
Transplanted with Chrebp/ BM
(A) Atherosclerotic lesion severity in the aortic root of HFD-fed Ldlr/ recipient
mice transplanted with WT or Chrebp/ BM (n = 10).
(B) mRNA expression in lesional macrophages isolated by laser microcapture
in these mice.
(C) Representative micrographs and quantification of TUNEL-positive signal
(green; arrows) in nuclei (blue) of aortic root lesions from these mice (magni-
fication 3500).
Results are mean ± SEM. *p < 0.05 compared to control.
CBM, typified by a slight decrease in sections containing no lesions
or valve lesions and a greater proportion of sections containing
foamcell rich lesions and sections containing advanced, complex
lesions characterized by compromised integrity of the media,
necrotic core formation, and cholesterol clefts (expressed as
the number of observations) (Figure 7A). Furthermore, Chrebp/
lesional macrophages isolated by laser capture microscopy
(LCM), which expressed CD68, but not the endothelial marker
CD31, showed increased mRNA expression of inflammatory cy-
tokines such as TNF-a, MCP-1, and MIP1a (Figure 7B). A trend
toward reduced Arg1 and Mrc1 mRNA expression was also
observed (data not shown). More strikingly, TUNEL staining
revealed five times more apoptotic cells in mice receiving
Chrebp/ BM (Figure 7C), reflecting the pro-survival role of
ChREBP inmaintainingmacrophage redox status. This correlated
with an increased necrotic area in these mice (1,819 ± 284 versus
3,665 ± 466 mm2/section in Ldlr/ mice receiving WT or
Chrebp/ BM, respectively). Together, these data suggest that
ChREBP-dependent metabolic reprogramming of lesional mac-
rophages controls atherosclerosis plaque complexity.
DISCUSSION
Atherosclerotic plaques that cause clinical events, so-called
vulnerable plaques, have a high macrophage content (Libby
et al., 1996; Moore and Tabas, 2011) that correlates with
enhanced 18FDG incorporation visualized by PET-CT imaging
(Rogers and Tawakol, 2011; Garcia-Garcia et al., 2014). How-
ever, the molecular mechanisms that link glucose utilization
to inflammation in macrophages are poorly understood in
the context of atherosclerosis. The present study reveals that
ChREBP, a glucose sensor transcription factor, is expressed
by macrophages and protects against macrophage inflamma-
tory responses and apoptosis induced by pro-atherogenic
stressors. Notably, our mechanistic studies have demonstrated
that macrophages lacking ChREBP show a dramatic decrease in
cellular glutathione content due to the loss of reducing energy
supplied through the production of NADPH. This leads to
increased ROS production and sustained NF-kB activation in
response to LPS in macrophages after ChREBP knockdown,
driving local and systemic inflammatory responses. Moreover,
in response to oxidative stress-induced apoptosis, macro-
phages in which ChREBP was silenced were more prone to cas-
pase dependent death, likely explaining the enhanced necrotic
core formation in plaques of mice transplanted with Chrebp/
BM. Together, our data establish a critical role for ChREBP in
preventing macrophage inflammation and apoptosis in athero-
sclerosis and demonstrate the importance of immune metabolic
flux in chronic inflammatory diseases.
When we initiated the present study, we hypothesized that
ChREBP could be a sensor of the high glycolytic rate of inflam-
matory macrophages (Fukuzumi et al., 1996; Gamelli et al.,
1996; Gautier et al., 2013; Nishizawa et al., 2014). This hypothe-
sis was driven by observations showing that ChREBP can be
regulated by glucose-derived metabolites in hepatocytes and
the fact that liver pyruvate kinase (LPK) is a ChREBP target
gene (Filhoulaud et al., 2013). Nevertheless, we first observed
that ChREBP was downregulated upon LPS treatment. Basalell Reports 13, 132–144, October 6, 2015 ª2015 The Authors 141
and LPS-stimulated ChREBP knockdownmacrophages also ex-
hibited higher glycolytic metabolites and enhanced expression
of glycolytic enzymes such as Hk2 and PKM2. This suggested
that macrophage PKM2, in contrast to hepatic LPK, was not a
transcriptional target of ChREBP, most likely because neogluco-
genesis is not present in macrophages and these cells do not
require fine-tuning of phosphoenolpyruvate (PEP) conversion
into pyruvate to avoid its recycling back to PEP for neoglucogen-
esis (Filhoulaud et al., 2013). The absence of such retro-control
in macrophages could also explain the lower expression of
ChREBP in these cells compared to hepatocytes. Interestingly,
ChREBP is a regulator of malic enzyme (ME)-dependent pyru-
vate cycling in hepatocytes (Ma et al., 2006; Burgess et al.,
2008) that reroutes TCA intermediates derived from pyruvate
back to pyruvate and transfers reducing equivalents from
NADH to NADP+ to generate NADPH (Lu et al., 2002). The regu-
lation of this pathway appears to be fully conserved in macro-
phages, as reduced ME expression and activity paralleled a
dramatic accumulation of malate in macrophages after ChREBP
silencing and was associated with a reduced NADPH/NADP ra-
tio. Alteration of this pathway could also contribute to the broken
Krebs cycle recently observed in LPS-stimulated macrophages
that could support the arginosuccinate shunt (Jha et al., 2015).
There are two alternative metabolic pathways that could have
contributed to the reduced NADPH/NADP ratio in these cells.
While the reduction of glucose by AR is observed in humans (Vik-
ramadithyan et al., 2005; Srivastava et al., 2009; Vedantham
et al., 2011), we observed a decrease in the PGD-dependent
nonoxidative phase of the PPP shunt that generates NADPH in
macrophages lacking ChREBP, revealing a mechanism of regu-
lation of NADPH production by ChREBP and illustrating the key
role of this transcriptional factor in maintaining the redox status
of macrophages.
By being a rheostat for cellular metabolism controlling cellular
redox status, ChREBP orchestrates a complex response to ex-
ternal pro-atherogenic stressors that require a high energy de-
mand, efficient anti-oxidant homeostasis, and lipid synthesis.
Interestingly, the mechanism underlying the increased LPS-
dependent inflammatory responses and LPS- and oxidized-
LDL-dependent death in macrophages lacking ChREBP was
found to be an amplified burst of oxidative stress secondary to
a broken TCA cycle and glutathione depletion, which is known
to be regenerated in an NADPH-dependent fashion. At the mo-
lecular level, the enhanced NF-kB activity in macrophages with
ChREBP silencing could be linked to ROS sensitivity (Morgan
and Liu, 2011), and ROS generation could also act as a first
‘‘hit’’ signal, pre-polarizing macrophages prior activation (Jais
et al., 2014) or sustaining JNK activation (Kamata et al., 2005;
Dhanasekaran and Reddy, 2008), altering the balance of life
and death in response to Toll-like receptor signaling in macro-
phages (Yvan-Charvet et al., 2010a; Moore and Tabas, 2011).
Glutathione depletion in macrophages has been previously
associated with atherosclerotic lesion formation in the setting
of AR overexpression (Vikramadithyan et al., 2005; Srivastava
et al., 2009; Vedantham et al., 2011). We now show that a
similar mechanism can be controlled by ChREBP-dependent
NADPH-glutathione regulation. Another interesting observation
was that ChREBP controls autophagy-dependent macrophage142 Cell Reports 13, 132–144, October 6, 2015 ª2015 The AuthorsM2 polarization, which could be the consequence of an altered
oxidative metabolism-dependent pre-programming of these
cells toward an M2-like phenotype (Jais et al., 2014) or an
impaired fatty acid synthesis limiting substrate availability for
lysosomal lipolysis (Huang et al., 2014). Future studies should
help to clarify this point and determine whether this mechanism
contributes to the accelerated atherosclerosis in mice trans-
planted with Chrebp/ BM (Liao et al., 2012). Together, our
studies extend the importance of immune metabolic flux beyond
macrophage inflammation in atherosclerosis by proposing that
(1) ChREBP could represent a functional metabolic shift between
M1 and M2 macrophage polarization in atherosclerosis and (2)
ChREBP could play a pivotal pro-survival role in macrophages,
with major implications for plaque necrosis and stability (Libby
et al., 1996; Moore and Tabas, 2011).
The role of macrophages in controlling hematopoietic and
myeloid cell mobilization from the BM to the spleen for extra-
medullary hematopoiesis has recently emerged. This function
represents an important pro-atherogenic mechanism that con-
tributes to the pool of circulating Ly6Chi monocytes that infiltrate
atherosclerotic plaques (Tall and Yvan-Charvet, 2015). Interest-
ingly, the increased plaque burden driven by an alteration in
macrophage behavior in mice transplanted with Chrebp/ BM
was associated with systemic inflammation dominated by an
increase in circulating inflammatory Ly6hi monocytes. A com-
petitive BM transplantation experiment suggested that this
phenotype was driven by extrinsic factors such as MCP-1 and
MCP-3 that were increased in the plasma and atherosclerotic
plaques of mice transplanted with Chrebp/ BM. These factors
could mediate the emigration of monocytes out of the BM and
their recruitment to inflammatory atherosclerotic plaques (Tsou
et al., 2007; Tacke et al., 2007; Swirski et al., 2007; Combadie`re
et al., 2008; Westerterp et al., 2013). Thus, this study provides
evidence of an additional antiatherogenic effect of ChREBP in
macrophages, acting as a positive feedback loop to control
monocytosis.
Together, these data demonstrate an unexpected role of
ChREBP in preventing macrophage inflammation and apoptosis
and indicate that activation of the ChREBP pathway may be a
potential therapeutic target to prevent the formation of complex
dangerous atheromata. In particular, it would be interesting to
determine whether such a therapeutic approach could have
additive value in the context of NASH, in which hepatic activation
of ChREBP may also protect against insulin resistance (Filhou-
laud et al., 2013).EXPERIMENTAL PROCEDURES
Materials and additional methods are available in Supplemental Experimental
Procedures.
Mice
Chrebp/ mice (B6.129S6-Mlxipltm1Kuy/J) that have been crossed to
C57BL/6J for 25 generations were obtained from The Jackson Laboratory. An-
imal protocols were approved by the Institutional Animal Care and Use Com-
mittee of Columbia University or were undertaken according to the Guidelines
for Care and Use of Experimental Animals in France. Animals had free access
to food and water and were housed in a controlled environment with a 12-hr
light-dark cycle and constant temperature (22C).
BM Transplantation
BM transplantation was performed as previously described (Yvan-Charvet
et al., 2010b) using BM fromWT andChrebp/ littermates. Briefly, the athero-
sclerosis studies were conducted in 10-week-old female Ldlr/ mice fed a
Western-type diet (TD88137) from Harlan Teklad for 11 weeks. Mice were al-
lowed to recover for 4 weeks after irradiation and BM transplantation before
diet studies were initiated. Body weight was recorded at indicated time points.
Mice were euthanized in accordance with the American Veterinary Association
Panel of Euthanasia. Spleen and epididymal adipose tissue weights were
determined at the time of sacrifice.
Histological Analysis of Proximal Aortas
Mice were sacrificed and heart was harvested. Heart was washed with PBS
then fixed with 4% paraformaldehyde. Heart was embedded in paraffin, and
5-mm sections of proximal aortas were performed using a Microm HM340E
microtome (Microm Microtech) and stained with H&E. Aortic lesion size of
each animal was calculated as the mean of lesion areas in six sections from
the same mouse using ImageJ software calibrated with parameters of the
Leica DM5500 B (Leica Microsystemes SAS) microscope. Atherosclerotic le-
sions were expressed in mm2 per section.
Macrophages Harvesting and Culture
WT mice were injected intraperitoneally with 3% thioglycolate to recruit mac-
rophages as previously described (Gautier et al., 2013). Briefly, after 3 days,
mice were sacrificed and peritoneal macrophages were harvested by a PBS
(Life Technologies) wash of the intraperitoneal cavity. Cells were filtered on a
42-mM cell strainer (VWR). Macrophages were cultured in DMEM 10% fetal
bovine serum 1% penicillin/streptomycin (Life Technologies).
Statistical Analysis
Data are shown as mean ± SEM. Statistical significance was performed using
Prism t test or ANOVA were performed according to the dataset. Results were
considered as statistically significant when p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.08.068.
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